Ex-EMA head Thomas Lönngren must wait two years before joining pharma firms
This article was originally published in Scrip
Executive Summary
Thomas Lönngren, the former head of the European Medicines Agency (EMA), will probably have to relinquish all or some of the commercial appointments that he has taken up since his departure from the agency. EMA said on 21 March that Mr Lönngren must wait two years before he takes up a position with the private sector pharmaceutical industry. The announcement follows controversy over a potential conflict of interest after Mr Lönngren joined private sector companies shortly after leaving the EMA.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.